On 23 December 2005, orphan designation (EU/3/05/340) was granted by the European Commission Novartis Europharm Limited, United Kingdom, for imatinib mesilate for the treatment of myelodysplastic / myeloproliferative diseases. Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in April 2012 on request of the sponsor.
The tool’s circuit board can overheat and melt the tool’s enclosure. If the tool is being held while overheating, it could present a risk of burn. Additionally, some tools may lose their speed control changing to high speed in use, turn on by themselves, or may not turn off, posing a personal injury hazard.
The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP).
myHealthbox™ is a leading provider of health information services to consumers and healthcare professionals.
myHealthbox™ provides a platform to access official Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC) documents on healthcare products including: human, animal and plants medications; drugs; herbal, homoeopathic and natural remedies; prescription and over-the-counter medicines; beauty products and cosmetics; supplements and medical devices.